Departments of Pediatric Oncology.
Children & Adolescent Hematology-Oncology Unit, Second Department of Pediatrics, School of Medicine, Aristotle University of Thessaloniki.
J Pediatr Hematol Oncol. 2023 Aug 1;45(6):322-326. doi: 10.1097/MPH.0000000000002625. Epub 2023 Jan 19.
Aim of this study was to evaluate the long-term therapeutic outcome and treatment-related complications in Hodgkin disease. We reviewed the medical records of 93 patients diagnosed with classic Hodgkin lymphoma, treated, and followed-up during the last 25 years. The cohort study included 49 males and 44 females with median age 11.8 years old (range: 3.95 to 17.42 y). The most common subtype was nodular sclerosis in 47/93 (50.5%). B symptoms were present in 15/93 (16.1%). From January 2009 until December 2020, 55 (59%) patients diagnosed with Hodgkin lymphoma were treated according to European Network for Pediatric Hodgkin Lymphoma (EURONET)-PHL-C1 protocol. Concerning outcome, a total of 89/93 patients are alive. Relapse occurred in 7/93. Second malignancies are reported in a total of 5 patients, 3 solid tumors (thyroid cancer, breast cancer, and osteosarcoma), and 2 acute myeloid leukemias. The overall survival and event-free survival for the whole cohort were 95.7% and 83.9%, respectively. Disease-free survival was 92.5%. Although a considerable high fraction of patients with Hodgkin disease can achieve continuous complete remission, they are at a high risk of developing long-term treatment-related complications. High curative rates as well as prevention of late effects can be achieved by implementation of individualized treatment strategies and innovative treatments.
本研究旨在评估霍奇金病的长期治疗效果和与治疗相关的并发症。我们回顾了过去 25 年期间诊断为经典霍奇金淋巴瘤、接受治疗和随访的 93 例患者的病历。这项队列研究包括 49 名男性和 44 名女性，中位年龄为 11.8 岁（范围：3.95 至 17.42 岁）。最常见的亚型是 93 例中的 47 例（50.5%）结节性硬化症。93 例中有 15 例（16.1%）存在 B 症状。2009 年 1 月至 2020 年 12 月，根据欧洲儿科霍奇金淋巴瘤网络（EURONET）-PHL-C1 方案治疗了 55 例（59%）霍奇金淋巴瘤患者。就结果而言，共有 89 例患者存活。93 例中 7 例复发。共有 5 例患者报告了第二恶性肿瘤，其中 3 例为实体瘤（甲状腺癌、乳腺癌和骨肉瘤），2 例为急性髓系白血病。整个队列的总生存率和无事件生存率分别为 95.7%和 83.9%。无病生存率为 92.5%。尽管相当一部分霍奇金病患者可以实现持续完全缓解，但他们存在发生长期治疗相关并发症的高风险。通过实施个体化治疗策略和创新治疗，可以实现较高的治愈率和预防晚期效应。
